Latest Announcements

Kalpataru Limited has announced its Q2 and H1 FY27 performance, with pre-sales at ₹1,258 crore and collections at ₹1,189 crore, representing a 9% year-on-year growth in collections. The company has launched a new premium residential project, Kalpataru Elaara, and has adopted the Maharashtra Government's Model Sub-Registration Office (SRO) framework.

Computer Age Management Services Ltd (CAMS) has announced its Q2 FY'27 consolidated profit up by 14.4% Y-o-Y, with operating revenue growing 10.0% Y-o-Y to ₹414.47 crore. The company recommends an interim dividend of ₹3.25/- per share.

Computer Age Management Services Limited has announced its Q2 FY27 consolidated profit up by 14.4% Y-o-Y, with an interim dividend of Rs. 3.25/- per share. The company's operating revenue grew 10.0% Y-o-Y to ₹414.47 crore, with EBITDA increasing 13.5% Y-o-Y to ₹190.86 crore. Mutual fund assets under management (AuM) grew 12.1% Y-o-Y to a record ₹58.4 lakh crore, with CAMS maintaining its leadership position with a 67% market share.

Seshaasai Technologies Limited has announced its Q2FY27 financial results, with revenue from operations increasing 15.0% YoY to ₹4,053.1 million and PAT growing 21.0% YoY to ₹697.3 million.

Fino Payments Bank Ltd has announced its investor presentation for the quarter and half year ended September 30, 2026, highlighting record quarterly renewal income, sustained growth in loan referral disbursals, and continued digital expansion.

Seshaasai Technologies Ltd reported Q2FY27 financial results with 15.0% YoY revenue growth and 21.0% YoY PAT growth, driven by strong performance in Payment Solutions, Communication & Fulfilment Solutions, and IoT Solutions.

Timken India Limited has submitted its unaudited financial results for the quarter and six months ended September 30, 2026, with a net profit after tax of Rs. 2,311.94 and a total comprehensive income of Rs. 2,295.25. The company has paid a final dividend of Rs. 2.50 per equity share.

Shelter Pharma Ltd has received export orders aggregating USD 3,64,335 from well-established customers, including Taha Drugs & Chemicals Co. Ltd, First Vet Veterinary Medicines Trading L.L.C, and Genet International. The orders are for the supply of nutraceutical and animal feed products, including Joemega Capsules, Foliman Tablet, All Vitamin Tablet, Electrolyte Dex C, Lactocal Gel Super, Livodin-12 Liquid, IMMUNO UP, NGK FORTE, and BUTA-B BOLUS.

Aditya Vision Limited has opened five new showrooms, taking its total to 219, marking its presence in Madhya Pradesh and West Bengal, and expanding its customer base and retail network.

Aditya Vision Ltd has opened five new showrooms, taking its total number of showrooms to 219. The new showrooms are located in Madhya Pradesh and West Bengal, marking the company's presence in the fifth and sixth states respectively. This expansion is expected to expand the company's footprint in new markets, broaden its customer base, enhance accessibility, and strengthen its retail network.

IndoStar Capital Finance Ltd announced its unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, with disbursements increasing by 51% YoY to INR 1,399 crore and AUM growing to INR 8,459 crore.

Gujarat Alkalies and Chemicals Ltd has started receiving hybrid power from a 6.6 MW hybrid power installation, part of its 75.9 MW Clean Max Renewable Hybrid Power Project.

Alivus Life Sciences Ltd has announced its Q2 FY27 results, with revenue growing 16.0% YoY, driven by healthy demand across all key markets and robust contributions from recent launches. The company has also reported a strong free cash flow of ₹2,702 Mn, leading to Cash and Cash Equivalents (including short term investments) of ₹10,116 Mn as of 30th September 2026.

Tamilnad Mercantile Bank Ltd has announced the transcript of its Q2 earnings conference call, where the bank reported a 27.25% year-on-year growth in total business, with net interest income up 4.38% and net profit at a record INR451 crores.

Alivus Life Sciences Limited has released its Q2 FY27 investor presentation, highlighting a 16.0% YoY revenue growth, driven by healthy demand across key markets and robust contributions from recent launches. The company reported a gross margin of 64.4%, up 420 bps QoQ and 670 bps YoY, and an EBITDA margin of 41.8%, up 520 bps QoQ and 880 bps YoY.

Alivus Life Sciences Ltd reported a 16.0% YoY revenue growth in Q2FY27, driven by broad-based momentum in the non-GPL business, with EBITDA margin at a record high of 41.8%. The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026.

Alivus Life Sciences Limited has announced its financial results for the second quarter and half-year, ended September 30, 2026, with revenue from operations for Q2FY27 at Rs. 6,820 Mn, a growth of 16.0% YoY, and EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%.

Alivus Life Sciences Ltd has announced its unaudited financial results for the second quarter and half year ended September 30, 2026, showing a net profit of ₹1,967.45 crore and ₹3,568.21 crore respectively.

Tamilnad Mercantile Bank Limited has informed the Exchange about the transcript of the earnings conference call hosted by the Bank on the Unaudited Financial Results of the Bank for the quarter and half year ended September 30, 2026, which has been made available on the Bank’s website.

Alivus Life Sciences Ltd has announced its unaudited financial results for the second quarter and half year ended September 30, 2026, showing a net profit of ₹1,967.45 crore and ₹3,568.21 crore respectively.